We and other research consistently identified FAK-YAP signaling axis as a general adaptive mechanism for resistance of tyrosine kinase inhibitors, including KRAS G12C inhibitor. Specifically, we demonstrated that KRAS G12C inhibition induces sustained activation of FAK-YAP and a combination therapy comprising KRAS G12C inhibition and IN10018 can prevent treatment resistance.

We explored opportunities to develop combination regimen and identified D-1553, a highly potent and selective KRAS G12C inhibitor from InventisBio, through preclinical testing. Based on strong anti-tumor effects across multiple tumor models, we established global strategic collaboration on clinical development of the innovative treatment regimen. Both drug candidates have been granted with Breakthrough Therapy Designation by NMPA in 2022.

This collaboration brings together the strengths of us and InventisBio in translational research and clinical development, to transform scientific innovation into treatment regimen with durable anti-cancer effects, for patients with KRAS G12C tumors.